Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bellevue, NE
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bellevue, NE
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
mi
from
Calgary,
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
mi
from
Calgary,
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
South End Community Health Center
mi
from
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
South End Community Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Dorchester House Multi-Service Center
mi
from
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Dorchester House Multi-Service Center
mi
from
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Codman Square Health Center
mi
from
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Codman Square Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Upham's Corner Health Center
mi
from
Dorchester, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Upham's Corner Health Center
mi
from
Dorchester, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Mattapan Community Health Center
mi
from
Mattapan, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Mattapan Community Health Center
mi
from
Mattapan, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Greater Roslindale Medical and Dental Center
mi
from
Roslindale, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Greater Roslindale Medical and Dental Center
mi
from
Roslindale, MA
Click here to add this to my saved trials
Effect of Fasting on the Asthma Inflammasome
Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effect of Fasting on the Asthma Inflammasome
Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
WCCT Global, LLC /ID# 162380
mi
from
Costa Mesa, CA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
WCCT Global, LLC /ID# 162380
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Sean N. Parker Center for Allergy and Asthma Research /ID# 162403
mi
from
Mountain View, CA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Sean N. Parker Center for Allergy and Asthma Research /ID# 162403
mi
from
Mountain View, CA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
IMMUNOe Research Centers /ID# 162381
mi
from
Centennial, CO
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
IMMUNOe Research Centers /ID# 162381
mi
from
Centennial, CO
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital /ID# 162378
mi
from
New Haven, CT
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital /ID# 162378
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Trials of Florida Inc /ID# 162393
mi
from
Tampa, FL
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Trials of Florida Inc /ID# 162393
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital /ID# 162400
mi
from
Chicago, IL
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital /ID# 162400
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Asthma & Allergy Center /ID# 162404
mi
from
Baltimore, MD
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Asthma & Allergy Center /ID# 162404
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Detroit Clinical Research Center, PC /ID# 162379
mi
from
Farmington Hills, MI
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Detroit Clinical Research Center, PC /ID# 162379
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
VA Western New York Healthcare System /ID# 162398
mi
from
Buffalo, NY
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
VA Western New York Healthcare System /ID# 162398
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
American Health Research /ID# 162401
mi
from
Charlotte, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
American Health Research /ID# 162401
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Health Care, P.A. /ID# 162405
mi
from
New Bern, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Health Care, P.A. /ID# 162405
mi
from
New Bern, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Wake Forest University School /ID# 162395
mi
from
Winston-Salem, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Wake Forest University School /ID# 162395
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions /ID# 162399
mi
from
Middleburg Heights, OH
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions /ID# 162399
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital /ID# 162397
mi
from
Philadelphia, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital /ID# 162397
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center /ID# 162385
mi
from
Pittsburgh, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center /ID# 162385
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Research Protocol Management Specialist /ID# 162377
mi
from
Pittsburgh, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Research Protocol Management Specialist /ID# 162377
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
MedTrial /ID# 162382
mi
from
Columbia, SC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
MedTrial /ID# 162382
mi
from
Columbia, SC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Upstate Pharmaceutical Research /ID# 162383
mi
from
Greenville, SC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Upstate Pharmaceutical Research /ID# 162383
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Respiratory and Sleep Disorders Specialists /ID# 162394
mi
from
The Woodlands, TX
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Respiratory and Sleep Disorders Specialists /ID# 162394
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
The University of Texas Health Science Center at Tyler /ID# 162384
mi
from
Tyler, TX
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
The University of Texas Health Science Center at Tyler /ID# 162384
mi
from
Tyler, TX
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
O&O Alpan LLC /ID# 162402
mi
from
Fairfax, VA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
O&O Alpan LLC /ID# 162402
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
ULB Erasme /ID# 162320
mi
from
Brussels,
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
ULB Erasme /ID# 162320
mi
from
Brussels,
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine /ID# 162396
mi
from
Saint Louis, MO
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine /ID# 162396
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Status: Enrolling
Updated:  12/31/1969
University of North Carolin at Chapel Hill
mi
from
Chapel Hill, NC
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Status: Enrolling
Updated: 12/31/1969
University of North Carolin at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13194
mi
from
Glendale, AR
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13194
mi
from
Glendale, AR
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10173
mi
from
Bakersfield, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10173
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Huntington Beach, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10147
mi
from
Long Beach, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10147
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11110
mi
from
Napa, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11110
mi
from
Napa, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10106
mi
from
Stockton, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10106
mi
from
Stockton, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10129
mi
from
Walnut Creek, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10129
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10133
mi
from
Denver, CO
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10133
mi
from
Denver, CO
Click here to add this to my saved trials